GSK2879552 is an orally available, irreversible, inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, GSK2879552 binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the dimethylated form of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor-suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. LSD1, overexpressed in certain tumor cells, plays a key role in tumor cell growth and survival.

 

Brand: BCM

 

Solubility: Soluble in DMSO (up to 25 mg/ml) or in Water (up to at least 25 mg/ml)

 

InChi Key: LRULVYSBRWUVGR-FCHUYYIVSA-N

 

Attribute
[Chem Name]	GSK2879552
[Synonym]	4-[[4-[[((1R,2S)-2-Phenylcyclopropyl)amino]methyl]piperidin-1-yl]methyl]benzoic acid
[CAS No.]	1401966-69-5
[Formula]	C23H28N2O2
[Molecular]	364.48
[Form]	White solid powder
[Storage]	-20°C

Goods Tag